Straits Times Index
3,292.69 +10.64 (+0.32%) S&P 500
5,018.39 -17.30 (-0.34%) Dow
37,903.29 +87.37 (+0.23%) Nasdaq
15,605.48 -52.34 (-0.33%) Bitcoin USD
57,875.66 -2,652.52 (-4.38%) CMC Crypto 200
1,273.11 -65.95 (-4.93%)
TGTX Jan 2025 5.000 call
| Previous close | 9.00 |
| Open | 12.30 |
| Bid | 11.10 |
| Ask | 11.50 |
| Strike | 5.00 |
| Expiry date | 2025-01-17 |
| Day's range | 11.00 - 13.19 |
| Contract range | N/A |
| Volume | |
| Open interest | 7.05k |
GuruFocus.comTG Therapeutics Inc (TGTX) Surpasses Revenue Estimates in Q1 2024, Despite Widening Net Loss
Comprehensive Analysis of TG Therapeutics' First Quarter Financial Performance
ZacksTG Therapeutics (TGTX) Reports Q1 Loss, Tops Revenue Estimates
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -133.33% and 15.59%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireTG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
First quarter 2024 BRIUMVI U.S. net revenue of $50.5 million, representing >25% quarter over quarter growth Total revenue for Q1 2024 of $63.5 million, including a $12.5 million milestone payment for BRIUMVI launch in first EU country New BRIUMVI prescriptions to the TG hub of over 1,250 for Q1 2024, representing >25% growth quarter over quarter Conference call to be held today, May 1, 2024, at 8:30 AM ET NEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Compan
